Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of two updosing schedules for ALK-Flex SQ in grass pollen allergic rhinoconjunctivitis
2008-006921-14Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- Nov 2008
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of ALK-Flex SQ in allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by ALK-Abelló. Primary endpoint: Change from baseline in specific IgE-blocking factor against Phleum pratense after seven injections. Started Nov 2008; status: completed.
02
Drugs
ALK-Flex SQ
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2008-006921-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006921-14.